Farmacoriflessioni
Farmaci, sperimentazioni, registri, nei tempi dell’emergenza del coronavirus
Drugs, clinical trials and registers in the time of the coronavirus emergency
Massimo Fontana1, Giovanna Zuin1, Antonio Addis2, Federico Marchetti3
1Clinica Pediatrica, Università di Milano-Bicocca; Fondazione Monza Brianza per il Bambino e la sua Mamma
2Dipartimento di Epidemiologia del Servizio Sanitario Regionale, Regione Lazio, Roma
3UOC di Pediatria e Neonatologia, Ospedale di Ravenna, AUSL della Romagna
Aprile 2020 - pagg. 232 -236
Abstract
Covid-19 is forcing medical doctors to deal with the urgent need to find clinical answers in an area where, unfortunately, there are still therapies with no evidence of efficacy and safety. In any case, they must make decisions and face the dilemma of immediately using any therapeutic options that has some plausibility of treatment or instead making clinical trial. However, the latter require formal steps and procedures. How do medical doctors understand which of these are essential and necessary? Is it really important to register the new clinical trials on the official platforms? Is this an unnecessary bureaucratic passage that can be avoided during the emergency phase? The present article tries to answer these questions by also addressing other critical issues related to clinical trials at a time when the good rules of clinical research must not be an obstacle to accessing the best available treatments.
Parole chiave
Suggerite dall'AI
Bibliografia
1. Chalmers I, Glasziou P. Avoidable waste in the production and reporting of research evidence. Lancet 2009;374(9683):86-9.
2. Dresser R. Clinical trial registration and the ICMJE. JAMA 2005;293(2):157.
3. Marchetti F, Lazzerini M. La registrazione degli studi clinici: una garanzia a tutela dei pazienti? Medico e Bambino 2005;24(6):348.
4. DeVito NJ, Bacon S, Goldacre B. Compliance with legal requirement to report clinical trial results on ClinicalTrials.gov: a cohort study. Lancet 2020;395(10221):361-9.
5. Volpi S, Naviglio S, Tommasini A. Covid-19 e riposta immune. Tra debolezze in difesa e errori in attacco. Medico e Bambino 2020;39(4):223-31.
6. Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020 Mar 20:105949 [Epub ahead of print].
7. Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 2020 Mar 1 [Epub ahead of print].
8. Cao B, Wang Y, Wen D, et al. Trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med 2020 Mar 18 [Epub ahead of print].
9. Wu J, Li W, Shi X, et al. Early antiviral treatment contributes to alleviate the severity and improve the prognosis of patients with novel coronavirus disease (COVID-19). J Intern Med 2020 Mar 27 [Epub ahead of print].
10. AIFA. Sperimentazioni cliniche - Covid-19. https://www.aifa.gov.it/sperimentazioni-cliniche-covid-19.
11. Addis A. Governare la ricerca medico-scientifica è un investimento per il Servizio Sanitario Nazionale. Medico e Bambino 2012;31(4):211-2.
12. Greenhalgh T, Koh GCH, Car J. Covid-19: a remote assessment in Primary Care. BMJ 2020 Mar 25;368:m1182.
13. Guiducci C, Marchetti F. Covid-19 e bambini: il punto dalla letteratura al 18 marzo. Medico e Bambino 2020;39(3):151-3.
14. Sinha IP, Harwood R, Semple MG, et al. Covid-19 infection in children. Lancet Respir Med 2020, Mar 27 [Epub ahead of print].
Corrispondenza: federico.marchetti@auslromagna.it